Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)

Breast Cancer Research and Treatment

Volumn 125, Issue 1, 2011, Pages 99-106

  Kim, Jeong Eun ^a   Ahn, Jin Hee ^a   Jung, Kyung Hae ^a   Kim, Sung Bae ^a   Kim, Hwa Jung ^b   Lee, Keun Suk ^c   Ro, Jung Sil ^c   Park, Yun Hee ^d   Ahn, Jin Suk ^d   Im, Young Hyk ^d   Im, Seock Ah ^e   Lee, Moon Hee ^f   Kim, Si Young ^g  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c National Cancer Center   (South Korea)

^d Samsung Medical Center   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Inha University   (South Korea)

^g Kyung Hee University   (South Korea)

Author keywords

Adjuvant chemotherapy; Amenorrhea; Bone loss; Breast cancer; Zoledronic acid

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; LAPATINIB; PACLITAXEL; PARATHYROID HORMONE; PROCOLLAGEN; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AMENORRHEA; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CHILL; CLINICAL OBSERVATION; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; FEMUR NECK; FEVER; HUMAN; JAW OSTEONECROSIS; KIDNEY FUNCTION; KOREA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; OPEN STUDY; OSTEOLYSIS; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ABSORPTIOMETRY, PHOTON; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR NECK; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; LUMBAR VERTEBRAE; OSTEOPOROSIS; PREMENOPAUSE; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TIME FACTORS; TREATMENT OUTCOME;

EID: 78651104412     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1201-8     Document Type: Article

References (28)

1. J Pfeilschifter IJ Diel 2000 Osteoporosis due to cancer treatment: pathogenesis and management J Clin Oncol 18 1570 1593 1:STN:280: DC%2BD3c3gtVGisw%3D%3D 10735906
2. RE Coleman 1997 Skeletal complications of malignancy Cancer 80 1588 1594 1:STN:280:DyaK1c%2Fis1Onuw%3D%3D 10.1002/(SICI)1097-0142(19971015)80:8+<1588: :AID-CNCR9>3.0.CO;2-G 9362426
3. EE Lower R Blau P Gazder R Tummala 1999 The risk of premature menopause induced by chemotherapy for early breast cancer J Womens Health Gend Based Med 8 949 954 1:STN:280:DC%2BD3c%2FgtFyltg%3D%3D 10534297
4. A Oleksik P Lips A Dawson ME Minshall W Shen C Cooper, et al. 2000 Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures J Bone Miner Res 15 1384 1392 1:STN:280:DC%2BD3M%2FhtF2jtg%3D%3D 10.1359/jbmr.2000.15.7.1384 10893688
5. J Bines D Oleske M Cobleigh 1996 Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer J Clin Oncol 14 1718 1729 1:CAS:528:DyaK28XjtFKitro%3D 8622093
6. AH Partridge HJ Burstein EP Winer 2002 Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer J Natl Cancer Inst Monogr 30 135 142
7. P Delmas R Balena E Confravreux C Hardouin P Hardy A Bremond 1997 Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study J Clin Oncol 15 955 962 1:CAS:528:DyaK2sXitFCgs7s%3D 9060533
8. CL Shapiro J Manola M Leboff 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer J Clin Oncol 19 3306 3311 1:CAS:528:DC%2BD3MXlvVamsr4%3D 11454877
9. JA Headley RL Theriault AD LeBlanc R Vassilopoulou-Sellin GN Hortobagyi 1998 Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy Cancer Invest 16 6 11 1:STN:280:DyaK1c7jsVGhsg%3D%3D 10.3109/07357909809039747 9474245
10. MR McClung P Geusens PD Miller H Zippel WG Bensen C Roux, et al. 2001 Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333 340 1:CAS:528:DC%2BD3MXht1Wlu7g%3D 10.1056/NEJM200102013440503 11172164 (Pubitemid 32107641)
11. S Adami V Bruni D Bianchini A Becorpi P Lombardi C Campagnoli, et al. 2000 Prevention of early postmenopausal bone loss with cyclical etidronate J Endocrinol Invest 23 310 316 1:CAS:528:DC%2BD3cXltV2kt7k%3D 10882149
12. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1535 1541 1:CAS:528: DyaK2sXisFCktQ%3D%3D 10.1016/S0140-6736(96)07088-2 8950879 (Pubitemid 26411651)
13. T Saarto C Blomqvist M Valimaki P Makela S Sarna I Elomaa 1997 Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens Br J Cancer 75 602 605 1:CAS:528: DyaK2sXhslWitrg%3D 9052418
14. GE-H Fuleihan M Salamoun YA Mourad A Chehal Z Salem Z Mahfoud, et al. 2005 Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial J Clin Endocrinol Metab 90 3209 3214 10.1210/jc.2004-1444 (Pubitemid 41014277)
15. SL Hines BA Mincey JA Sloan SP Thomas E Chottiner CL Loprinzi, et al. 2009 Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer J Clin Oncol 27 1047 1053 1:CAS:528: DC%2BD1MXktVCju70%3D 10.1200/JCO.2008.19.1783 19075260
16. MFX Gnant B Mlineritsch G Luschin-Ebengreuth S Grampp H Kaessmann M Schmid, et al. 2007 Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 25 820 828 1:CAS:528: DC%2BD2sXjvVKmtLw%3D 10.1200/JCO.2005.02.7102 17159195 (Pubitemid 350002882)
17. AM Brufsky LD Bosserman RR Caradonna BB Haley CM Jones HC Moore, et al. 2009 Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 77 85 1:CAS:528:DC%2BD1MXmtlahtLY%3D 10.3816/CBC.2009.n.015 19433387
18. CL Shapiro S Halabi G Gibson DJ Weckstein J Kirshner WM Sikov, et al. 2008 Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 7980 J Clin Oncol (Meeting Abstracts) 26 512
19. DL Hershman DJ McMahon KD Crew S Cremers D Irani G Cucchiara, et al. 2008 Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer J Clin Oncol 26 4739 4745 1:CAS:528:DC%2BD1cXhtlSqsb7N 10.1200/JCO.2008.16.4707 18711172
20. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
21. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen, et al. 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 1809 1:CAS:528:DC%2BD2sXht1Kit7nN 10.1056/NEJMoa074941 17878149 (Pubitemid 350044800)
22. SM Ott 2005 Long-term safety of bisphosphonates J Clin Endocrinol Metab 90 1897 1899 1:CAS:528:DC%2BD2MXisVOhu7w%3D 10.1210/jc.2005-0057 15758064 (Pubitemid 40464065)
23. DL Hershman DJ McMahon KD Crew T Shao S Cremers L Brafman, et al. 2010 Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment J Clin Endocrinol Metab 95 559 566 1:CAS:528:DC%2BC3cXitVaisrw%3D 10.1210/jc.2009-1366 20022990
24. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CYC Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301 1:CAS:528:DC%2BD2MXisVOhsr0%3D 10.1210/jc.2004-0952 15598694 (Pubitemid 40463979)
25. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg, et al. 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 1491 10.1359/jbmr.0707onj 17663640 (Pubitemid 351229318)
26. N Kohno K Aogi H Minami S Nakamura T Asaga Y Iino, et al. 2005 Zoledronic acid significantly reduces skeletal complications compared with placebo in japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial J Clin Oncol 23 3314 3321 1:CAS:528: DC%2BD2MXlsVyiu7w%3D 10.1200/JCO.2005.05.116 15738536
27. JR Gralow 2007 Bone density in breast cancer: when to intervene? J Clin Oncol 25 3194 3197 10.1200/JCO.2007.12.3430 17577014 (Pubitemid 47325601)
28. RE Coleman 2007 Emerging strategies in bone health management for the adjuvant patient Semin Oncol 34 S11 S16 1:CAS:528:DC%2BD1cXht1ejsrY%3D 10.1053/j.seminoncol.2007.10.003 18068485 (Pubitemid 350192627)